sameAs
Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor bindingSer19-->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic peopleImpact of apolipoprotein A5 variants on statin treatment efficacyAPOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levelsCurrent practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: data from the MedPed CZ database and the Czech population.SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.New strategies in the treatment of dyslipidemia: do we know how?The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals.Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events.Low prevalence of type 2 diabetes mellitus among patients with high levels of high-density lipoprotein cholesterol.A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.Rare variants in known and novel candidate genes predisposing to statin-associated myopathy.Interaction of common sequence variants and selected risk factors in determination of HDL cholesterol levels.Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia.Increase of inflammatory state in overweight adults with combined hyperlipidemia.Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children.Hypertriglyceridemia: interaction between APOE and APOAV variants.MLXIPL variant in individuals with low and high triglyceridemia in white population in Central EuropeFamilial defective apolipoprotein B-100 homozygote with premature coronary atherosclerosis. A case report 1Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registryThe authors of lipid guidelines are at odds with their own recommendationsGene variants at FTO, 9p21, and 2q36.3 are age-independently associated with myocardial infarction in Czech menAssociation between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech populationUse of ezetimibe results in more patients reaching lipid targets without side effectsFTO and MC4R gene variants determine BMI changes in children after intensive lifestyle interventionVariant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacyGenetic determination of triglyceridemia with special focus on apolipoprotein gene variantsChanges in Hemostatic Variables Induced by Estrogen Replacement Therapy: Comparison of Transdermal and Oral Administration in a Crossover-Designed StudyFolic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patientsComparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
P50
Q24314838-EDD9D02A-358E-44F0-9BDB-290748315DF8Q24676508-92064EC4-6E16-4D2B-B59F-5B9B26DBF3AFQ28248690-BEE34A66-C6FF-4DFC-871B-C6336BF69A75Q28286099-22007D16-A6AA-4BB4-9B20-4A9E46C38265Q33646780-B13194E7-1773-4ED5-B0D2-4096ADB8ECECQ33800434-FE8BBB44-981F-4854-BDAB-0D6F6032301EQ35669829-8002F0EC-514B-4E95-9DC9-9F6ED9C5AF9CQ35998904-C9261A5B-37A9-423B-A2D8-9A2D2951BB58Q37433102-E40AD2B7-3914-4980-BAB1-AB2768D40D5EQ37873935-BD19526D-4C54-4FBB-BB91-EDCE322F50A4Q38111010-F87D5AF5-E0A3-4005-93D0-E09A095EE364Q38575410-01DA4320-D92E-441B-8082-483EDE09F3C5Q40703907-A6BC0F83-810F-49C2-8855-2A22A5DB7F5AQ43098318-165972D1-46C4-4E88-A4A5-E6D3A9015DF1Q44249484-7B9F18F1-2618-4015-9F42-09EBADD75FDBQ44676662-0FE9FC6D-48AE-4E52-8B6B-E2C4F475A8F3Q46473859-FD1F8862-CF8C-4AE9-8AC6-BF2AD4217A12Q47297793-AEF16A40-4467-4413-9B03-4AE6354066B3Q54657345-147A36D2-F3F0-40FD-9137-F04C95056532Q57241431-5644B518-787F-4B41-B58D-44B8E7D07977Q57557852-E65DCB37-DF0F-4EDF-A80D-CF496A10683DQ60156152-C60B4F27-B740-4772-9D8E-F9DD4AC1A3B8Q60156153-5BE72114-3AD1-4964-BDAF-5D0F8FFBEFB6Q60156154-7A02A9D8-A1F5-4CE1-8A8C-A2FCB02C4538Q60156155-79338C1A-B0F5-4FA7-A125-6AC3C72E57A0Q60156156-709A475B-C94C-49A5-BEE8-B4F4732EFAA2Q60156158-14436E1B-ED5C-4243-8FDF-3855B9648FAFQ60156159-235783A7-1C2C-402A-B93A-D4D8C74F09C8Q60156160-D74D9E88-AB6A-42AD-8B9A-C98A97E8F60BQ60156164-112E8DBE-BABC-4EF9-ADB0-2DE8E2ABA91CQ60156169-CC6FACB1-9995-47E8-BB1A-DB16F29078C8Q91759712-F0C77356-CA49-4A55-A5C6-3BE60977FC39
P50
description
Czech doctor
@en
arts uit Tsjechië
@nl
dochtúir Seiceach
@ga
dokter asal Republik Ceko
@id
médicu checu
@ast
tschechischer Arzt
@de
český lékař
@cs
طبيب تشيكي
@ar
name
Michal Vrablík
@ast
Michal Vrablík
@cs
Michal Vrablík
@de
Michal Vrablík
@en
Michal Vrablík
@fr
Michal Vrablík
@ga
Michal Vrablík
@sl
Vrablik Michal
@es
Vrablik Michal
@nl
type
label
Michal Vrablík
@ast
Michal Vrablík
@cs
Michal Vrablík
@de
Michal Vrablík
@en
Michal Vrablík
@fr
Michal Vrablík
@ga
Michal Vrablík
@sl
Vrablik Michal
@es
Vrablik Michal
@nl
altLabel
M Vrablik
@en
Michal Vrablik
@en
Vrablik M
@en
Vrablik Michal
@ast
Vrablik Michal
@en
Vrablik Michal
@sl
prefLabel
Michal Vrablík
@ast
Michal Vrablík
@cs
Michal Vrablík
@de
Michal Vrablík
@en
Michal Vrablík
@fr
Michal Vrablík
@ga
Michal Vrablík
@sl
Vrablik Michal
@es
Vrablik Michal
@nl
P214
P1053
B-4590-2017
P106
P1153
6701669648
P21
P213
0000 0000 5779 8632
P214
P31
P3829
P496
0000-0002-7226-1926
P569
1973-01-01T00:00:00Z
1973-05-01T00:00:00Z
P691
P735
P7859
viaf-85697021